CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...